Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer
Lung Cancer, Volume 49, No. 2, Year 2005
Notification
URL copied to clipboard!
Description
Purpose: The objective of this trial was to compare two vinorelbine-based doublets with carboplatin (CBDCA-VC) or with gemcitabine (VG) in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Patients and Methods: A total of 316 patients with advanced NSCLC previously untreated were randomized to either vinorelbine 30 mg/m2 D1,8 with carboplatin AUC 5 D1 (VC) or vinorelbine 25 mg/m2 with gemcitabine (VG) 1000 mg/m2 both given D1,8 every 3 weeks. The primary endpoint was response rate with secondary parameters being survival (OS), progression-free survival (PFS), tolerance and clinical benefit. Results: The median number of cycles was four in each arm with a total of 1268 cycles. The objective response (OR) on intent-to-treat was 20.8% in VC and 28% in VG (p = 0.15). Median PFS was 3.9 months in VC and 4.4 months (mo) in VG (p = 0.18). Median survival was significantly longer (p = 0.01) for VG with 11.5 mo compared to 8.6 mo in VC with 1 year survival at 48.9 and 34.4%, respectively. Tolerance was better in the VG arm as compared to the VC patients. Four toxic deaths were recorded in the VC group. Clinical benefit response rate was 32.4% compared to 40.9% in 111 and 110 evaluable patients in VC and VG, respectively. Conclusion: VG compared to VC resulted in a similar overall response rate, favourable median survival and a better toxicity profile. For non-cisplatin-based chemotherapy, VG is a useful alternative. © 2005 Elsevier Ireland Ltd. All rights reserved.
Authors & Co-Authors
Tan, Eng Huat
Singapore, Singapore City
National Cancer Centre, Singapore
Szczésna, Aleksandra
Poland, Otwock
Mazowieckiego Centrum Leczenia Chorób Płuc I Gruzlicy w Otwocku
Krzakowski, M. J.
Poland, Warsaw
Maria Sklodowska-curie National Research Institute of Oncology
Macha, Hans Nicol
Germany, Hemer
Lungenklinik Hemer
Gatzemeier, Ulrich
Germany, Grosshansdorf
Krankenhaus Großhansdorf
Mattson, Karin V.
Finland, Helsinki
Helsinki University Hospital
Wernli, Martin
Switzerland, Aarau
Kantonsspital Aarau
Reiterer, Pavel
Czech Republic
Mazaryk Hospital
Hui, Rina
Australia, Sydney
Westmead Hospital
von Pawel, Joachim V.
Germany, Gauting
Asklepios Fachkliniken
Bertetto, Oscar
Italy, Turin
Azienda Ospedaliera Universitaria 'molinette' Di Torino
Pouget, Jean Christophe
France, Castres
Pierre Fabre Recherche et Devéloppement
Burillon, Jean Philippe
France, Castres
Pierre Fabre Recherche et Devéloppement
Parlier, Yolaine
France, Castres
Pierre Fabre Recherche et Devéloppement
Abratt, Raymond Pierre
South Africa, Observatory
Groote Schuur Hospital
Statistics
Citations: 58
Authors: 15
Affiliations: 13
Identifiers
Doi:
10.1016/j.lungcan.2005.03.029
ISSN:
01695002
Research Areas
Cancer
Environmental